SCHEMBL113163

SCHEMBL113163

NCCc1ccc(O)c(S(N)(=O)=O)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 5/20 0.60
MAPK1 P28482 3/20 0.60
KDM4E B2RXH2 3/20 0.60
ADRA2A P08913 3/20 0.60
SLC6A2 P23975 3/20 0.60
DRD2 P14416 3/20 0.60
DRD1 P21728 3/20 0.60
TDP1 Q9NUW8 3/20 0.60
MAPT P10636 2/20 0.60
DRD4 P21917 2/20 0.60
DRD5 P21918 2/20 0.60
DRD3 P35462 2/20 0.60
RECQL P46063 2/20 0.60
SLC6A3 Q01959 2/20 0.60
ALDH1A1 P00352 2/20 0.60
HTR1A P08908 2/20 0.60
APEX1 P27695 2/20 0.60
TP53 P04637 1/20 0.60
ADRB2 P07550 1/20 0.60
CYP2D6 P10635 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL142841 0.98 TAAR1 (0.58) TAAR1MAPK1KDM4EADRA2ASLC6A2
SCHEMBL11669534 0.86 BACE1 (0.57) TAAR1MAPK1KDM4EADRA2ASLC6A2
SCHEMBL8173017 0.84 KDM4E (0.40) TAAR1MAPK1KDM4EADRA2ASLC6A2
SCHEMBL28873594 0.81 CA2 (0.53) CA12CA1CA2CA4CA6
SCHEMBL3769908 0.80 CA12 (0.52) TAAR1MAPK1KDM4EADRA2ASLC6A2
SCHEMBL111618 0.80 CA12 (0.52) TAAR1MAPK1KDM4EADRA2ASLC6A2
Dopamine SCHEMBL3114891 0.79 KDM4E (0.81) TAAR1MAPK1KDM4EADRA2ASLC6A2
Dopamine SCHEMBL9241925 0.79 KDM4E (0.81) TAAR1MAPK1KDM4EADRA2ASLC6A2
SCHEMBL16822117 0.76 TAAR1 (0.58) TAAR1MAPK1KDM4EADRA2ASLC6A2
SCHEMBL142264 0.76 KDM4E (0.62) TAAR1MAPK1KDM4EADRA2ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
WO-2010106016-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2010-09-23 WO disclosed
US-3943254-A ALPHA-AMINOMETHYL-4-HYDROXY-3-SULFAMYL BENZYL ALCOHOLS OR 4-HYDROXY-3-SULFAMYL-PHENETHYLAMINE SMITHKLINE CORPORATION (US) 1976-03-09 US disclosed
US-3860647-A {60 -Aminomethyl-4-hydroxy-3-sulfamyl-benzyl alcohols and 4-hydroxy-3-sulfamyl phenethylamines SMITHKLINE BECKMAN CORPORATION 1975-01-14 US disclosed
US-3860647-A {60 -Aminomethyl-4-hydroxy-3-sulfamyl-benzyl alcohols and 4-hydroxy-3-sulfamyl phenethylamines SMITHKLINE BECKMAN CORPORATION 1975-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK TAAR1 4526/4885MAPK1 332/4885KDM4E 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.